Corbus Pharmaceuticals Hldgs Inc (CRBP) Stock Price, Quote & News

Company Profile

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a highly peripherally re...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 963 0100

Fax: 617 663 6085

Website: www.corbuspharma.com

Address:

500 River Ridge Drive, Norwood, United States

birdmine Jan. 5 at 10:52 PM

$CRBP https://finance.yahoo.com/news/corbus-pharmaceuticals-present-44th-annual-123000833.html

0 · Reply

birdmine Jan. 5 at 3:54 PM

$CRBP sigh.

1 · Reply

birdmine Jan. 5 at 12:52 PM

$CRBP I can say with all honesty that this stock gives me nightmares!!!

0 · Reply

BlackjackAces Jan. 2 at 11:53 PM

$CRBP Im doing owning bios - sold out of every one of these stocks. For every one that hits, 20 suck cock. After lots of years of trading Ive realized its just an awful overall investment. The oppty cost as well of holding these for years and years alone bites

1 · Reply

olafszulcc Jan. 1 at 8:43 PM

$CRBP The market is currently speculating. If biotech comes back into fashion, CRBP will skyrocket.

0 · Reply

elmarklimke Jan. 1 at 7:24 PM

$CRBP The shares sold for $15 in the fall, so the current price is a sale. No one would buy these shares unless they expected a profit. Current price is a sale.

1 · Reply

birdmine Jan. 1 at 1:04 AM

$CRBP this year is in the books.

0 · Reply

birdmine Dec. 31 at 2:07 PM

$CRBP Well, this is the last trading day of the year. This was the only bitter pill for me. The rest of it was pretty sweet. Trading let me retire this year at 53 and I couldn’t be happier. Hopefully, 2026 lets us get out of this stock and we keep growing and grinding!! Good luck everyone. See you in 2026!!😆😆😆

0 · Reply

birdmine Dec. 30 at 4:56 PM

$CRBP boy. This and 2025 is going out on a fizzle!!

1 · Reply

birdmine Dec. 29 at 2:53 PM

$CRBP will we break over 8.50 before the new year?

0 · Reply

Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 11, 2025, 4:42 PM EST - 26 days ago

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Phase 1a Single-Ascending and Multiple-Ascending Dose Data Transcript

Dec 11, 2025, 7:00 AM EST - 27 days ago

Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss

Dec 10, 2025, 4:01 PM EST - 27 days ago

Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025

Nov 6, 2025, 8:00 AM EST - 2 months ago

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

Nov 5, 2025, 11:42 AM EST - 2 months ago

Corbus Pharmaceuticals: Data Update And Fundraising Efforts Do Not Diminish The Thesis

Oct 31, 2025, 2:40 AM EDT - 2 months ago

Corbus Pharmaceuticals Announces Pricing of Public Offering

Oct 30, 2025, 4:31 PM EDT - 2 months ago

Corbus Pharmaceuticals Announces Proposed Public Offering

Oct 20, 2025, 5:05 PM EDT - 2 months ago

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses CRB-701 Data and Insights in Head and Neck Cancer Panel Transcript

Oct 18, 2025, 3:00 AM EDT - 2 months ago

Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

Sep 16, 2025, 8:00 AM EDT - 4 months ago

FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma

Jun 25, 2025, 8:00 AM EDT - 7 months ago

Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

Jun 24, 2025, 4:05 PM EDT - 7 months ago

Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium

Jun 17, 2025, 3:42 PM EDT - 7 months ago

Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data?

May 22, 2025, 8:00 AM EDT - 8 months ago

Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 19, 2025, 8:00 AM EDT - 8 months ago

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

AKTX QURE

Mar 28, 2025, 8:00 AM EDT - 10 months ago

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

Feb 14, 2025, 7:30 AM EST - 11 months ago

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

Feb 11, 2025, 7:30 AM EST - 11 months ago

Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

Jan 28, 2025, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference

Jan 6, 2025, 8:00 AM EST - 1 year ago

Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 9, 2024, 7:00 AM EST - 1 year ago

Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

$FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer$

Dec 3, 2024, 7:00 AM EST - 1 year ago

FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer

Nov 11, 2024, 4:12 AM EST - 1 year ago

Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

Sep 26, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit

Sep 23, 2024, 2:01 PM EDT - 1 year ago

Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now

Aug 26, 2024, 12:00 PM EDT - 1 year ago

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

AMGN GPCR SRRK VKTX

Aug 20, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Jul 30, 2024, 8:50 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Jun 3, 2024, 1:03 PM EDT - 1 year ago

Corbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025

Jun 1, 2024, 10:00 AM EDT - 1 year ago

SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024

May 30, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

May 23, 2024, 5:05 PM EDT - 1 year ago

Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting

May 9, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

May 7, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 1, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum

Apr 24, 2024, 4:05 PM EDT - 1 year ago

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting

Apr 2, 2024, 8:00 AM EDT - 1 year ago

Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Mar 6, 2024, 8:00 AM EST - 2 years ago

Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit

Feb 28, 2024, 8:00 AM EST - 2 years ago

Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

Feb 6, 2024, 9:50 AM EST - 2 years ago

Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 2, 2024, 4:01 PM EST - 2 years ago

Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 30, 2024, 7:13 AM EST - 2 years ago

Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug

Jan 29, 2024, 2:17 PM EST - 2 years ago

Corbus Pharmaceuticals: Surging On The Back Of Great News, But I See Dark Clouds

Jan 29, 2024, 7:18 AM EST - 2 years ago

Corbus Pharmaceuticals (CRBP) is up 250%: what's up with the stock?

Jan 26, 2024, 7:30 AM EST - 2 years ago

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024

birdmine Jan. 5 at 10:52 PM

$CRBP https://finance.yahoo.com/news/corbus-pharmaceuticals-present-44th-annual-123000833.html

0 · Reply

birdmine Jan. 5 at 3:54 PM

$CRBP sigh.

1 · Reply

birdmine Jan. 5 at 12:52 PM

$CRBP I can say with all honesty that this stock gives me nightmares!!!

0 · Reply

BlackjackAces Jan. 2 at 11:53 PM

1 · Reply

olafszulcc Jan. 1 at 8:43 PM

$CRBP The market is currently speculating. If biotech comes back into fashion, CRBP will skyrocket.

0 · Reply

elmarklimke Jan. 1 at 7:24 PM

$CRBP The shares sold for $15 in the fall, so the current price is a sale. No one would buy these shares unless they expected a profit. Current price is a sale.

1 · Reply

birdmine Jan. 1 at 1:04 AM

$CRBP this year is in the books.

0 · Reply

birdmine Dec. 31 at 2:07 PM

0 · Reply

birdmine Dec. 30 at 4:56 PM

$CRBP boy. This and 2025 is going out on a fizzle!!

1 · Reply

birdmine Dec. 29 at 2:53 PM

$CRBP will we break over 8.50 before the new year?

0 · Reply

VeinVow Dec. 27 at 1:30 PM

$CRBP Confidence will depend on whether guidance becomes dependable; balance‑sheet optionality should not erode — measurable traction would outweigh rhetoric. Durability will separate winners from speculation.

0 · Reply

MistralMoney Dec. 26 at 2:41 PM

$CRBP Risk appetite is present but conditioned on validation. Governance alignment should reduce uncertainty over time. Clear execution would attract broader institutional participation. Stronger outcomes appear only when priorities stay focused.

1 · Reply

FiNgAz Dec. 24 at 3:49 PM

$CRBP Consolidating for quite a while but think it will eventually make its move back in the right direction. Hang in there!

0 · Reply

forgpwp123 Dec. 22 at 7:01 PM

Adding more of $CRBP toast. Bullish and something brewing

0 · Reply

birdmine Dec. 22 at 12:30 PM

$CRBP all I want for Christmas is for this to shoot up!!!😆😆

0 · Reply

birdmine Dec. 19 at 10:27 PM

$CRBP sigh!!!

0 · Reply

birdmine Dec. 19 at 12:06 PM

$CRBP sign. Hoping for the best…

0 · Reply

SuperGreenToday Dec. 19 at 4:03 AM

$CRBP Share Price: $8.10 Contract Selected: Jun 18, 2026 $10 Calls Buy Zone: $1.23 – $1.52 Target Zone: $2.21 – $2.70 Potential Upside: 69% ROI Time to Expiration: 181 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

moosegoose Dec. 19 at 12:44 AM

$CRBP time for the move back over $10+

0 · Reply

JackRogers Dec. 18 at 8:34 PM

$CRBP small biotech mid range, bulls need a higher low and breakout with expanding volume before this becomes more than a bounce

0 · Reply

Power2k Dec. 18 at 2:10 PM

$PYXS 5 discontinued patients are all over-weighted, dosing will be adjusted well based on body weight going forward. Purely oversold and overreaction by market. $MRUS $CRBP

0 · Reply

Power2k Dec. 18 at 2:07 PM

$PYXS MICVO + Keytruda: 71% Confirmed ORR, 100% DCR in R/M HNSCC - best data ever seen so far in combo treatment. $MRUS $BCAX $CRBP

0 · Reply

Market Cap	138.14M
Revenue (ttm)	0.00
Net Income (ttm)	-40.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	146,200
Avg Vol	458,750
Day's Range	N/A - N/A
Shares Out	17.55M
Stochastic %K	46%
Beta	2.77
Analysts	Strong Sell
Price Target	$42.33